Cellistic News and Resources

Cellistic, a specialist in induced pluripotent stem cell (iPSC)-based therapies, has launched the Echo-NK platform to support the large-scale manufacture of allogeneic Natural Killer (NK) cell treatments. The new platform builds on the company’s Echo Platform introduced in 2023. The

Cellistic, an innovator in iPSC-based off-the-shelf cell therapy development and manufacturing, has achieved GMP certification for its advanced facility in Belgium. The certification, granted by the Belgian Federal Agency for Medicines and Health Products (FAMHP) under EMA guidelines, reflects the